Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company headquartered in San Francisco, California, focused on discovering and developing novel medicines that address immunological dysfunction in autoimmune and chronic inflammatory diseases. The company leverages its expertise in immunology to design immunomodulatory drugs aimed at enhancing, regulating, or suppressing immune activity to achieve targeted clinical benefits.

Nektar's primary product candidate is rezpegaldesleukin (REZPEG, or NKTR-358), a first-in-class regulatory T cell stimulator currently undergoing Phase 2b clinical trials for atopic dermatitis and alopecia areata, and a Phase 2 clinical trial for Type 1 diabetes mellitus. The pipeline also includes preclinical programs such as NKTR-0165 and NKTR-0166, bivalent antibody programs targeting autoimmune and rheumatic disorders, respectively, and NKTR-422 for inflammation resolution. Additionally, Nektar is evaluating NKTR-255, an IL-15 receptor agonist, in several clinical trials for cancer in collaboration with partners.

Recent notable activities for Nektar Therapeutics include several public offerings in April 2026, which raised significant capital. The company reported its fourth quarter and full-year 2025 financial results in March 2026 and is scheduled to announce first-quarter 2026 results in May 2026. Positive Phase 2b data for rezpegaldesleukin in atopic dermatitis and alopecia areata have supported plans for Phase 3 studies to commence in the second quarter of 2026. Howard W. Robin serves as the President and Chief Executive Officer.